BUDZ WEED, INC.
Services-Commercial Physical & Biological Research · OTC · SEC CIK 1393772 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.2%
TTM EPS YoY-33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-216.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets301.6%
Debt / equity—
Current ratio0.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-170.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | — |
| Cost of revenue | $0 | $0 | $0 | $0 | — |
| Gross profit | $0 | $0 | $0 | $0 | — |
| SG&A expense | $1.13M | $351,116 | $394,617 | $567,159 | $797,683 |
| Operating income | -$1.33M | -$529,992 | -$770,568 | -$1.51M | -$2.80M |
| Interest expense | — | $5,070 | $45,274 | $117,124 | $39,244 |
| Pretax income | -$1.37M | -$510,317 | — | -$1.53M | -$2.84M |
| Income tax | $33 | $399 | $980 | $0 | — |
| Net income | -$1.37M | -$510,716 | -$31,557 | -$1.53M | -$2.84M |
| EBITDA | -$1.31M | -$507,406 | -$718,176 | -$1.39M | -$2.67M |
| EPS (basic) | — | -0.00 | -0.00 | -0.01 | -0.02 |
| EPS (diluted) | -0.01 | -0.00 | -0.00 | — | -0.02 |
| Weighted avg. shares (diluted) | 135.92M | 124.13M | 123.71M | — | 116.73M |
| Balance sheet | |||||
| Cash & equivalents | $33,130 | $159,355 | $290,409 | $315,826 | $19,654 |
| Receivables | — | — | — | — | $822 |
| Current assets | $47,705 | $189,891 | $319,886 | $342,075 | $41,918 |
| PP&E, net | $476,467 | $496,354 | $516,340 | $1.21M | $1.88M |
| Goodwill | — | — | $0 | $0 | $0 |
| Intangibles | $30,983 | $33,583 | — | — | $40,576 |
| Total assets | $559,906 | $738,366 | $904,062 | $1.63M | $1.96M |
| Current liabilities | $1.25M | $959,372 | $648,753 | $1.46M | $1.34M |
| Total liabilities | $1.25M | $959,372 | $648,753 | $1.46M | $1.34M |
| Shareholders' equity | -$688,361 | -$221,006 | $255,309 | $169,796 | $617,500 |
| Shares outstanding | 148.53M | 125.43M | 123.48M | 123.48M | 119.22M |
| Cash flow statement | |||||
| Operating cash flow | -$195,136 | -$415,524 | -$1.07M | -$812,975 | -$568,914 |
| Capital expenditure | — | — | $10,000 | $0 | $271,233 |
| Free cash flow | — | — | -$1.08M | -$812,975 | -$840,147 |
| Investing cash flow | — | — | $1.63M | $1.26M | -$271,233 |
| Financing cash flow | $70,103 | $285,269 | -$587,979 | -$148,667 | $848,617 |
| Depreciation & amortization | $22,487 | $22,586 | $52,392 | $111,426 | $129,789 |
| Stock-based compensation | $800,000 | $20,000 | — | — | $2.00M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.